Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Anebulo gets FDA nod for Phase 3 in acute cannabinoid intoxication

The FDA provided positive feedback to Anebulo Pharmaceuticals (NASDAQ:ANEB) for its Phase 3 program of ANEB-001 in patients suffering from acute cannabinoid intoxication (ACI) and substance abuse.

August 21, 2023

Developments

MindBio receives first LSD batch for home psychedelic clinical trials

MindBio Therapeutics (CSE:MBIO; Frankfurt:WF6) received its first batch of MB22001 ready for take-home use in Phase 2 psychedelic microdosing clinical trials. MB22001 is a proprietary titratable form of lysergic acid...

August 18, 2023

Developments

Reviva completes Phase 3 enrollment for brilaroxazine in schizophrenia

Reviva Pharmaceuticals (NASDAQ:RVPH) completed enrollment in the pivotal Phase 3 RECOVER study, evaluating brilaroxazine for schizophrenia, with 402 patients enrolled across 40 sites in the U.S., Europe, and Asia. “We...

August 17, 2023

Developments

Minghui enrolls first patient in Phase 3 trial for atopic dermatitis

Closely-held Minghui Pharmaceutical enrolled the first patient in the Phase 3 clinical study for MH004 cream targeting mild-to-moderate atopic dermatitis, a prevalent skin condition. The randomized, double-blind, and...

August 17, 2023

Developments

Keystone Dental Holdings to combine with Check-Cap

Closely-held Keystone Dental Holdings agreed to a definitive business combination with Check-Cap (NASDAQ:CHEK), with stockholders of Keystone becoming majority holders of the combined company. If completed, the business...

August 17, 2023

Developments

Eyenovia acquires U.S. rights for ocular asset from Formosa Pharmaceuticals

Eyenovia (NASDAQ:EYEN) entered an agreement with Taiwan-based Formosa Pharmaceuticals (TWO:6838) to acquire the exclusive U.S. rights to distribute and sell Formosa’s APP13007 (clobetasol propionate ophthalmic...

August 16, 2023

Markets

Leerink ups Centessa PT to $11 from $6 on pipeline prospects

Leerink Partners raised its price target for Centessa Pharmaceuticals (NASDAQ:CNTA) to $11 from $6, and reiterated an “outperform” rating, citing an improved outlook for its pipeline. The stock closed at $6.62 on Aug...

August 15, 2023

Markets

Leerink starts Turnstone Biologics at MP; PT $13

Leerink Partners initiated coverage of Turnstone Biologics (NASDAQ:TSBX) with a “market perform” rating and $13 price target. The stock closed at $11.73 on Aug. 14. “We see potential in Turnstone’s selected tumor...

August 15, 2023

Developments

iBio posts positive in vivo proof of concept in 3 immuno-oncology programs

iBio (NYSEA:IBIO) reported positive preclinical in vivo data for three immuno-oncology candidates – an anti-EGFRvIII, CCR8 and a bispecific TROP-2 x CD3 – advancing the three programs to clinical candidate...

August 14, 2023

Developments

FDA clears Revance’s DAXXIFY injection for cervical dystonia

The FDA approved the first therapeutic indication for Revance Therapeutics’ (NASDAQ:RVNC) DAXXIFY for injection for the treatment of cervical dystonia in adults. Cervical dystonia is a chronic, debilitating disease in...

August 14, 2023

Developments

Anixa to present ovarian cancer CAR-T therapy at CAR-TCR Summit

Dr. Pamela Garzone, chief development officer of Anixa Biosciences (NASDAQ:ANIX) will present, “Developing a CAR-T for Ovarian Cancer and Other Solid Tumors,” at the 8th Annual CAR-TCR Summit in Boston...

August 14, 2023

Developments

Plus Therapeutics posts positive Phase 1 data in leptomeningeal metastases

Plus Therapeutics (NASDAQ:PSTV) reported positive data from the ReSPECT-LM clinical study evaluating the company’s lead radiotherapeutic, rhenium (Re-186) obisbemeda, for the treatment of leptomeningeal metastases (LM)...

August 11, 2023

Anebulo gets FDA nod for Phase 3 in acute cannabinoid intoxication

MindBio receives first LSD batch for home psychedelic clinical trials

Reviva completes Phase 3 enrollment for brilaroxazine in schizophrenia

Minghui enrolls first patient in Phase 3 trial for atopic dermatitis

Keystone Dental Holdings to combine with Check-Cap

Eyenovia acquires U.S. rights for ocular asset from Formosa Pharmaceuticals

Leerink ups Centessa PT to $11 from $6 on pipeline prospects

Leerink starts Turnstone Biologics at MP; PT $13

iBio posts positive in vivo proof of concept in 3 immuno-oncology programs

FDA clears Revance’s DAXXIFY injection for cervical dystonia

Anixa to present ovarian cancer CAR-T therapy at CAR-TCR Summit

Plus Therapeutics posts positive Phase 1 data in leptomeningeal metastases

General

More